Evotec beLAB1407 was launched in 2021 with the Universities of Birmingham, Dundee, Edinburgh and Nottingham, and they will now be joined by the Universities of Bristol and Glasgow, as well as Queen Mary University of London. Under the partnership, the University of Bristol will benefit from access to funding, expertise, and drug discovery and development platforms spanning multiple disease areas.
Evotec is a life science company that works to discover highly effective therapeutics and make them available to patients. The BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) partnership is designed to tap into academic science to accelerate the formation of spin-out companies and generate collaborations with pharmaceutical and biotech companies.